Discover and read the best of Twitter Threads about #myelomaxi
Most recents (2)
We had an early Christmas with our team's latest work out in @BloodJournal. We investigated the benefit patients derive from Lenalidomide Maintenance in context of tumour genetics. ashpublications.org/blood/article-…
Our aim was to interrogate clinically accessible markers that can support care discussions. The Len Maintenance registration trials included limited genetics. We investigated 556 patients with extended genetics randomized post ASCT to Len Maint or Observation in #MyelomaXI 
Extended genetics included all HRCA del(1p), gain(1q) & t(14;16)/t(14;20) + standard t(4;14) and del(17p), demonstrating the challenge of reporting on individual genetic markers in #myeloma – e.g. >50% of ‘t(4;14) patients’ also carried at least one other HRCA (=double hit).
Just as there is notably wider interest in chr1q abnormalities in myeloma now than when our data was published: here again a link to the excellent work chr1q copy number evolution and its clinical impact from James Croft on #UKMRA #MyelomaXI trial nature.com/articles/s4137…
By investigating new copy number aberrations detected at relapse in 179 matched presentation-relapse tumours from #MyelomaXI, James discovered newly detected 1q aberrations to be most frequent, followed by del13q and del17p. As previous tweet shows, with equal adverse OS.
DigitalMLPA, the method used to detect these, is sensitive and allowed to look up how many of new 1q relapses had sub-clonal gain(1q) at presentation: answer is some, but not the majority.
